In the article on targeting LPAAT-β in gynecologic cancer in the October 15, 2005 issue of Cancer Research (1), it should be noted that Dr. Gregory M. Springett's research was performed at the Memorial Sloan-Kettering Cancer Center, Developmental Chemotherapy Laboratory, Department of Medicine; he is currently at the H. Lee Moffitt Cancer Center, Drug Discovery Program and Department of Interdisciplinary Oncology. Also, the following should have appeared in the Acknowledgment: We thank the Memorial Sloan-Kettering Cancer Center Molecular Cytology Core for assistance with the confocal microscopy studies, Cyrus Hedvat for constructing the tissue microarrays, Mario Leitao for assistance in obtaining clinical follow-up information, and Jeni Moses for assistance in compound screening.

1
Springett GM, Bonham L, Hummer A, Linkov I, Misra D, Ma C, Pezzoni G, Di Giovine S, Singer J, Kawasaki H, Spriggs D, Soslow R, Dupont J. Lysophosphatidic acid acyltransferase-β is a prognostic marker and therapeutic target in gynecologic malignancies.
Cancer Res
2005
;
65
:
9415
–25.